Predictive Factors for the Prognosis of Vogt-Koyanagi-Harada Disease

Ocul Immunol Inflamm. 2023 Oct;31(8):1687-1693. doi: 10.1080/09273948.2022.2159841. Epub 2023 Jan 10.

Abstract

Purpose: To identify the prognostic factors in Vogt-Koyanagi-Harada (VKH) disease.

Methods: This study included 23 patients (46 eyes) with acute-phase VKHdivided into two subgroups: Group 1; acute-resolved (10 patients), group 2; chronic-recurrent (13 patients).

Results: Mean age were 29.5 ± 10.2 years in group 1, 35.8 ± 12.2 years group 2 (p = .033). Best-corrected visual acuity with logMAR at admission was 0.91 ± 0.65 in group 1, 0.88 ± 0.62 in group 2 (p = .798), and improved to 0.08 ± 0.24, 0.18 ± 0.6, respectively (p = .557). Extraocular findings were detected in 30% in group 1, and 53.8% in group 2 at the time of admission (p = .108). All patients were treated with 1 g/day 3-5 days intravenous steroid, and 10 patients had immunomodulatory treatment. Initiation of immunomodulatory therapy did not affect the prognosis (p = .676).

Conclusion: Older patients and/or who developed extraocular findings at the presentation were more prone to show recurrences.

Keywords: Optical coherence tomography; Vogt–Koyanagi–Harada disease; predictive factor; prognosis; uveitis.

MeSH terms

  • Adult
  • Drug Therapy, Combination
  • Humans
  • Prognosis
  • Retrospective Studies
  • Uveomeningoencephalitic Syndrome* / diagnosis
  • Uveomeningoencephalitic Syndrome* / drug therapy
  • Visual Acuity
  • Young Adult